The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multi-institutional phase II open-label study of AMG 479 in advanced carcinoid and pancreatic neuroendocrine tumors.
Matthew Kulke
Consultant or Advisory Role - Ipsen; Lexicon; Novartis; Pfizer
Research Funding - Novartis
Jennifer A. Chan
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
Jeffrey A. Meyerhardt
No relevant relationships to disclose
Charles S. Fuchs
No relevant relationships to disclose
Thomas Adam Abrams
No relevant relationships to disclose
Eileen Regan
No relevant relationships to disclose
Rachel Brady
No relevant relationships to disclose
Jill M. Weber
No relevant relationships to disclose
Tiffany Campos
No relevant relationships to disclose
Larry Kvols
Honoraria - Novartis
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis
Honoraria - Genentech
Research Funding - Amgen; Novartis; Pfizer